Topical formulation for a jak inhibitor
AssigneesIncyte Corporation, Incyte Holdings Corporation
InventorsBhavnish PARIKH, Bhavesh Shah, Krishnaswamy Yeleswaram
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Claims31
1-82. (canceled)
A method of treating a skin disorder in a human patient in need thereof, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6;
- and
- wherein treating is one or more of inhibiting the skin disorder and ameliorating the skin disorder.
A method of inhibiting JAK1 and/or JAK2 in a human patient suffering from a skin disorder, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6.
A method of treating atopic dermatitis in a human patient, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6;
- and
- wherein treating is one or more of inhibiting atopic dermatitis and ameliorating atopic dermatitis.
A method of treating atopic dermatitis in a human patient, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6;
- and
- wherein treating is one or more of inhibiting atopic dermatitis and ameliorating atopic dermatitis.
Dependencies are inferred from the claim text.